Hepatology On The Nile

Cairo Marriott Hotel

24-25 September, 2014

 

Obtain 12 CME Hours From The EACCME

This event was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME)

 

ECMEC Hours Mutually Recognized by the American Medical Association in the USA and The Royal College of Physicians and Surgeons in Canada

 

 

 

 

 

 

Day 1, Wednesday, 24 September 2014

 

Session I: Advances in Hepatitis C (1)

 

 

 

Towards realistic estimates of HCV incidence in Egypt

 

Romulus Breban,

Institut Pasteur, Paris, France

 

 

 

 

 

 

Changing the epidemiology of Hepatitis C with Treatment: The Case for Egypt

 

Homie Razavi,

Center of Disease Analysis, Colorado, USA

 

 

 

 

 

Update on current results of interferon-free regimens in patients with hepatitis C

 

Geoffrey Dusheiko,

Royal Free Hospital, London, UK

 

 

 

 

 

Metabolic syndrome & hepatitis C

 

Daniel Dhumeaux,

Paris XII University, Créteil, France

 

 

 

 

 

 

Session II: Advances in Hepatitis C (2)

 

 

 

 

Review of EASL practice guidelines for treatment of hepatitis C

 

Xavier Forns

Hospital Clinic, Barcelona, Spain

 

 

 

 

 

Next generation therapy for hepatitis C genotype 4

 

Tarek Asselah

Paris VII University, Clichy, France

 

 

 

 

 

 

HCV: Treat Now or Wait?

 

Ashley Brown

Imperial College, London, UK

 

 

 

 

 

 

Decompensated cirrhosis in the era of directly acting antiviral agents

 

Tarek Hassanein

Southern California Liver Centers California, USA

 

 

 

 

 

Session III: Advances in Hepatitis B (1)

 

 

 

 

Treatment of HBV flares

 

Rafael Esteban

Hospital Universitario Vall d'Hebron, Barcelona, Spain

 

 

 

 

 

 

Hepatitis delta virus: Treatments and guidelines

 

Maria Buti,

Hospital Universitario Vall d'Hebron, Barcelona, Spain

 

 

 

 

 

HBV decompensated liver disease: can all patients be salvaged?

 

Rafael Esteban,

Hospital Universitario Vall d'Hebron, Barcelona, Spain

 

 

 

 

 

Clinical application of HBsAg quantification

 

Tarek Asselah

Paris VII University, Clichy, France

 

 

 

 

 

Session IV: Miscellaneous

 

 

 

Application, utility and validation of a new histological system for classification of NAFLD in patients with metabolic syndrome

 

Pierre Bedossa

Paris VII University, Clichy, France

 

 

 

 

Spleen and liver stiffness measurement can predict clinical complications in compensated cirrhotic patients

 

Davide Festi

University of Bologna, Bologna, Italy

 

 

 

 

 

Managing overlap syndrome

 

Piero Almasio

University of Palermo, Palermo, Italy

 

 

 

 

 

 

Liver transplantation in Egypt

 

Ayman Yosry,

Kasr Al Aini School of Medicine, Cairo, Egypt

 

 

 

 

 

 

Session V: Public Policy and Hepatitis C

 

 

 

 

National Strategy for Control and Prevention of Viral Hepatitis:

An Update

 

Manal El-Sayed,

Ain Shams University and MOH, Cairo, Egypt

 

 

 

 

National Committee for Control of Viral Hepatitis: Treatment Guidelines and Hope for Eradication

 

Wahid Doss,

Cairo University and NCCVH, Cairo, Egypt

 

 

 

 

 

Day 2, Thursday, 25 September 2014

 

Session I: Advances in Hepatitis B (2)

 

 

 

 

Should we treat hepatitis B patients only on guidelines?

 

Ashley Brown

Imperial College, London, UK

 

 

 

 

 

 

Treatment and cure forms part of the control of the disease

 

Geoffey Dusheiko

Royal Free Hospital, London, UK

 

 

 

 

HBV clinical outcome and its relation to the host genomics

 

Ayman Abdou

King Saud University, Riyadh, Saudi Arabia

 

 

 

 

 

 

Session II: Challenges in the management of liver disease

 

 

 

Management of portal vein thrombosis in liver cirrhosis

 

Roberto de Franchis

University of Milan, Milan, Italy

 

 

 

 

 

Challenges in hepatic encephalopathy

 

Simon Taylor-Robinson

Imperial College, London, UK

 

 

 

 

 

 

 

Autoimmune hepatitis: difficult-to-treat

 

Piero Almasio

University of Palermo, Palermo, Italy

 

 

 

 

 

Challenges in management of portal hypertension

 

Roberto de Franchis

University of Milan, Milan, Italy

 

 

 

 

 

Session III: Hepatocellular Carcinoma

 

 

 

HCC Biomarkers

 

Simon Taylor-Robinson

Imperial College, London, UK

 

 

 

 

 

State of the art update on HCC

 

Massimo Colombo

University of Milan, Milan, Italy

 

 

 

 

Session IV: Advances in Hepatitis C (3)

 

 

 

 

State of art lecture: Situation of hepatitis C in Egypt

 

Gamal Esmat

Kasr Al Aini School of Medicine, Cairo, Egypt

 

 

 

 

 

 

Confronting HCV with Novel Antiviral Agents- Beyond Sofosbuvir

 

Raymond F. Schinazi

Emory University School of Medicine, Atlanta, USA

 

 

 

 

 

APASL consensus recommendations of hepatic fibrosis 2014

 

Gamal Shiha

Mansoura University , Egypt

 

 

 

 

Session V: Putting Progress into Practice for HCV Care in Egypt

 

 

 

 

HCV guidelines: from paper to practice

 

Ashley Brown

Imperial College, London, UK

 

 

 

 

 

HCV co-infection: no longer a special population?

 

Karine Lacombe

Université Pierre et Marie Curie, Paris, France

 

 

 

 

Can we take HCV out of the transplant equation?

 

Massimo Colombo

University of Milan, Milan, Italy

 

 

 

 

 

Linking care to cure in difficult-to-reach populations

 

Peter Buggisch

Livercenter, Hamburg, Germany

 

 

 

 

 

DEBATE: Will the availability of new DAAs really mean the end of IFN and/or RBV?

 

Yes

Peter Buggisch

Livercenter, Hamburg, Germany

 

No

Ashley Brown

Imperial College, London, UK

 

 

Summary and Discussion

 

Massimo Colombo

University of Milan, Milan, Italy

 

 

 

 

 

 

 

 

Session VI: Putting Progress into Practice for HBV Care in Egypt

 

 

 

Introduction

 

Geoffrey Dusheiko,

Royal Free Hospital, London, UK

 

 

 

 

 

 

How Far Can Therapy Take Us?

 

Maria Butti

Hospital Universitario Vall d'Hebron, Barcelona, Spain

 

 

 

 

Looking beyond clinical trials – the”real world‟ experience

 

Florian van Bömmel

University of Leipzig, Leipzig, Germany

 

 

 

DEBATE: Is finite therapy a realistic goal in HBV?

 

Yes

Henry Chan

Chinese University of Hong Kong

 

No

Florian van Bömmel

University of Leipzig, Leipzig,

Germany

 

 

 

Looking toward future prospects for cure

 

Henry Chan

Chinese University of Hong Kong, Hong Kong

 

 

 

 

 

 

Closing Remarks

 

Geoffrey Dusheiko,

Royal Free Hospital, London, UK

 

 

 

 

 

© National Liver Institute 2014